| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Avenzo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $445.85M | Series B | 9/22/2025 | $60M | $616.96M | $2.22 | OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital, NEA, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital | ||||
 | Epic Sciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $606.66M | Series A-3 | 12/29/2023 | $20.9M | $94.14M | $3.00 | Undisclosed Investors | ||||
 | Gameto | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117M | Series C | 8/12/2025 | $44M | $234.3M | $7.31 | Overwater Ventures, Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia | ||||
 | Orca Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $541.19M | Series F | 1/9/2026 | $136.35M | $2.4B | $54.99 | Lightspeed Venture Partners | ||||
 | Origin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Scorpion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.02B | Series C-2 | 7/16/2024 | $24.31M | $821.83M | $2.54 | Frazier Life Sciences, Lightspeed Venture Partners, Willett Advisors, Omega Funds, Vida Ventures, Atlas Venture, Abingworth, Fidelity, Boxer Capital, EcoR1 Capital, Surveyor Capital, Invus, Wellington Management, Nextech Invest, OrbiMed, Logos Capital, Woodline Partners LP, Casdin Capital | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | ||||
 | ArsenalBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $2.44B | Series C | 9/4/2024 | $327.5M | $1.66B | $18.58 | ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVIDIA, Luma Group, T. Rowe Price Associates, Rock Springs Capital, Parker Institute for Cancer Immunotherapy, SoftBank, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, Hitachi Ventures | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | Biosplice Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Circle Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $348.74M | Series E-1 | 8/6/2026 | $92.5M | $269.89M | $0.27 | Undisclosed Investors | ||||
 | Cytonics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Ultima Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Alloy Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.24M | Series E-1 | 4/15/2026 | $30M | $1B | $26.17 | 8VC, JIC Venture Growth Investments, Echo Capital, Mubadala Capital, Presight Capital, Thiel Capital, Founders Fund, Alexandria Venture Investments, Gaingels, Ulysses Diversified Holdings | ||||
 | Alzheon | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $371.22M | Series E | 6/12/2024 | $100M | $1.25B | $62.71 | Alerce Medical Technology Partners | ||||
 | Encoded Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $945.89M | Series F | 8/3/2026 | $275M | $629.69M | $3.40 | Undisclosed Investors | ||||
 | Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.5M | Series C | 6/25/2024 | $100M | $438.18M | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | ||||
 | Hemab Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Lycia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $277.05M | Series D | 6/10/2026 | $75M | $388.52M | $2.04 | Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, Venrock | ||||
 | Marea | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190M | Series B | 6/18/2024 | $152.89M | $267.31M | $1.45 | Sofinnova Investments, Forbion Capital Partners, Perceptive Advisors, venBio, Alpha Wave Global, Omega Funds, Citadel, Third Rock Ventures | ||||
 | Rénibus Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $148.41M | Series B | 7/17/2025 | $90M | $238.38M | $3.06 | Undisclosed Investors | ||||
 | XtalPi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $396.39M | Series D | 6/21/2024 | $130.47M | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | ||||